Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Imunon, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

INVESTORS AND STAKEHOLDERS INVITED TO ATTEND IN PERSON IN NEW YORK CITY OR VIA LIVE WEBCAST ON MONDAY, NOVEMBER 10TH AT 8:00 A.M. ET

IMUNON R&D DAY: OPPORTUNITY TO HEAR CLINICAL TRIAL INVESTIGATORS DISCUSS SIGNIFICANT POTENTIAL OF IMNN-001 TO REDEFINE OVARIAN CANCER TREATMENT

LAWRENCEVILLE, N.J., NOV. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT THE COMPANY WILL HOST A CONFERENCE CALL AT11:00 A.M.

IMUNON TO HOLD THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE CONFERENCE CALL ON THURSDAY, NOVEMBER 13, 2025

INVESTOR EVENT IN NEW YORK CITY TO PROVIDE UPDATE ON PIVOTAL PHASE 3 STUDY OF IMNN-001; OFFERING IN-PERSON OR VIRTUAL ATTENDANCE ON NOVEMBER 10, 2025

IMUNON ANNOUNCES WEBCAST OF IN-PERSON R&D DAY HIGHLIGHTING PROGRESS ON OVATION 3 STUDY IN PURSUIT OF FIRST FRONTLINE IMMUNOTHERAPY FOR ADVANCED OVARIAN CANCER

TRIALS-IN-PROGRESS POSTER OF ONGOING PIVOTAL PHASE 3 TRIAL OF DNA-MEDIATED IMMUNOTHERAPY ACCEPTED AT BOTH IGCS AND ESMO CONGRESS 2025 LAWRENCEVILLE, N.J., OCT. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT IT HAS BEEN INVITED TO PRESENT A TRIALS-IN-PROGRESS ABSTRACT ON THE ONGOING PHASE 3 OVATION 3 CLINICAL TRIAL OF IMNN-001, ITS INVESTIGATIONAL THERAPY FOR THE TREATMENT OF WOMEN WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER, AT THE 2025 ANNUAL GLOBAL MEETING OF THE INTERNATIONAL GYNECOLOGIC CANCER SOCIETY (IGCS), BEING HELD NOVEMBER 5-7, 2025 IN CAPE TOWN, SOUTH AFRICA.

IMUNON TO PRESENT PHASE 3 OVATION 3 STUDY OF IMNN-001 IN ADVANCED OVARIAN CANCER AT IGCS 2025 ANNUAL GLOBAL MEETING

IMNN-001 PROGRAM IS CURRENTLY ADVANCING ITS OVATION 3 PIVOTAL PHASE 3 TRIAL PER PLAN LAWRENCEVILLE, N.J., OCT. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT NEW TRANSLATIONAL DATA FROM THE PHASE 2 OVATION 2 CLINICAL TRIAL OF IMNN-001, ITS INVESTIGATIONAL THERAPY FOR THE TREATMENT OF WOMEN WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER, WILL BE PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING, BEING HELD NOVEMBER 5-9, 2025 IN NATIONAL HARBOR, MARYLAND.

IMUNON TO PRESENT NEW TRANSLATIONAL DATA FROM PHASE 2 OVATION 2 STUDY OF IMNN-001 AT SITC 40TH ANNUAL MEETING

INVESTOR EVENT TO PROVIDE UPDATE ON PIVOTAL PHASE 3 STUDY OF IMNN-001 TO BE HELD IN NEW YORK CITY ON NOVEMBER 10, 2025 PROGRAM WILL FEATURE PRESENTATIONS FROM OVARIAN CANCER THOUGHT LEADERS, PHASE 3 STUDY INVESTIGATORS, ONCOLOGY AND STATISTICAL EXPERTS LAWRENCEVILLE, N.J., OCT. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT IT WILL HOST AN R&D DAY FOR INVESTORS AT THE HARVARD CLUB (35 WEST 44TH STREET) IN NEW YORK CITY ON NOVEMBER 10, 2025, BEGINNING AT 8:00 A.M.

IMUNON HOSTS R&D DAY HIGHLIGHTING PROGRESS ON OVATION 3 STUDY IN PURSUIT OF FIRST FRONTLINE IMMUNOTHERAPY FOR ADVANCED OVARIAN CANCER

COMPANY SEEKS STRATEGIC PARTNERS TO ADVANCE NOVEL PLACCINE TECHNOLOGY LAWRENCEVILLE, N.J., OCT. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY FOCUSED ON DEVELOPING NON-VIRAL DNA-MEDIATED IMMUNOTHERAPIES AND EVALUATING AN ADAPTATION OF THE PLATFORM'S POTENTIAL AS A NEXT-GENERATION VACCINE, TODAY ANNOUNCED THAT MEMBERS OF ITS LEADERSHIP TEAM WILL DELIVER ORAL PRESENTATIONS HIGHLIGHTING IMNN-101, ITS INVESTIGATIONAL DNA PLASMID VACCINE BASED ON THE COMPANY'S PROPRIETARY PLACCINE TECHNOLOGY PLATFORM, INCLUDING PROOF-OF-CONCEPT CLINICAL TRIAL RESULTS AT THE FOLLOWING UPCOMING VACCINE CONFERENCES: 5TH EDITION OF INTERNATIONAL VACCINES CONGRESS (IVC) KEYNOTE ORAL PRESENTATION TITLE: A PROMISING NOVEL APPROACH TO DNA VACCINES PRESENTING AUTHOR: KHURSHEED ANWER, PH.D.

IMUNON INVITED TO PRESENT PLACCINE DNA TECHNOLOGY PROOF-OF-CONCEPT DATA IN PLATFORM PRESENTATIONS AT LEADING VACCINE CONFERENCES

PRESTIGIOUS EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONFERENCE TRIALS-IN-PROGRESS SESSION PIVOTAL OVATION 3 TRIAL OF ITS DNA-MEDIATED IMMUNOTHERAPY IN NEWLY DIAGNOSED PATIENTS UNDERWAY COMPANY ON TRACK WITH ESTABLISHED PLANS TO ACCELERATE PATIENT RECRUITMENT LAWRENCEVILLE, N.J., OCT. 14, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT A TRIALS-IN-PROGRESS ABSTRACT ON THE ONGOING PHASE 3 OVATION 3 CLINICAL TRIAL OF IMNN-001, ITS INVESTIGATIONAL THERAPY FOR THE TREATMENT OF WOMEN WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER, WAS ACCEPTED FOR POSTER PRESENTATION AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2025, BEING HELD OCTOBER 17-21, 2025 IN BERLIN, GERMANY.

IMUNON TO PRESENT PHASE 3 OVARIAN CANCER STUDY OF IMNN-001 AT ESMO CONGRESS

RESULTS FROM OVATION 2 STUDY REINFORCE IMNN-001 EFFICACY BENEFITS OBSERVED IN THE CLINIC AND UNIQUE MECHANISM OF ACTION, PRODUCING KEY ANTI-CANCER IMMUNE CYTOKINES POST-TREATMENT

IMUNON PRESENTS IMNN-001 PHASE 2 TRANSLATIONAL DATA IN ADVANCED OVARIAN CANCER DEMONSTRATING 13-MONTH OS EXTENSION VIA TUMOR MICRO-ENVIRONMENT SHIFT

OVATION 3 PIVOTAL PHASE 3 TRIAL IS CURRENTLY ADVANCING IMNN-001, WITH SEVERAL PATIENTS BEING TREATED LAWRENCEVILLE, N.J., SEPT. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT NEW TRANSLATIONAL DATA FROM THE PHASE 2 OVATION 2 STUDY OF IMNN-001, ITS INVESTIGATIONAL THERAPY FOR THE TREATMENT OF WOMEN WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER, WILL BE PRESENTED AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) SPECIAL CONFERENCE IN CANCER RESEARCH: ADVANCES IN OVARIAN CANCER RESEARCH, BEING HELD SEPTEMBER 19-21, 2025, IN DENVER, COLORADO.

IMUNON TO PRESENT NEW TRANSLATIONAL DATA OF IMNN-001 SUPPORTING PHASE 3 TRIAL OF IMMUNOTHERAPY FOR OVARIAN CANCER AT AACR SPECIAL CONFERENCE IN CANCER RESEARCH

LAWRENCEVILLE, N.J., AUG. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT OF ITS DNA-MEDIATED IMMUNOTHERAPY, TODAY ANNOUNCED THAT THE COMPANY HAS REGAINED COMPLIANCE WITH THE MINIMUM BID PRICE REQUIREMENT FOR CONTINUED LISTING ON THE NASDAQ CAPITAL MARKET FOLLOWING CONFIRMATION FROM THE NASDAQ HEARINGS PANEL. AS A RESULT, IMUNON COMMON STOCK WILL CONTINUE UNINTERRUPTED TRADING ON THE NASDAQ CAPITAL MARKET.

IMUNON SUCCESSFULLY REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE LISTING REQUIREMENT

INVESTORS ARE REMINDED THAT SHAREHOLDERS OF RECORD AS OF AUGUST 7, 2025, WILL RECEIVE A 15% STOCK DIVIDEND PAYMENT LAWRENCEVILLE, N.J., AUG. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON , INC. (NASDAQ: IMNN), A CLINICAL-STAGE COMPANY IN PHASE 3 DEVELOPMENT WITH ITS DNA-MEDIATED IMMUNOTHERAPY, EARLIER TODAY REPORTED FINANCIAL RESULTS FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED JUNE 30, 2025, AND HIGHLIGHTED RECENT BUSINESS UPDATES, INCLUDING PROGRESS IN ADVANCING PHASE 3 CLINICAL DEVELOPMENT OF ITS LEAD CANDIDATE IMNN-001 IN NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND THE INTRODUCTION OF A 15% STOCK DIVIDEND PAYMENT TO SHAREHOLDERS.

IMUNON RECAPS HIGHLIGHTS FROM 2025 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL

STOCK DIVIDEND ISSUED TO IMUNON SHAREHOLDERS REFLECTS CONFIDENCE IN CLINICAL PROGRAMS, LONG-TERM GROWTH STRATEGY AND DEDICATION TO REWARDING SHAREHOLDERS FIRST PATIENT DOSED IN PHASE 3 OVATION 3 STUDY OF IMNN-001 FOR TREATMENT OF NEWLY DIAGNOSED ADVANCED OVARIAN CANCER COMPANY TO HOLD CONFERENCE CALL TODAY AT 11:00 A.M. ET LAWRENCEVILLE, N.J.

Imunon, Inc.

IMNN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Imunon, Inc.

IMNN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMNN